{"classes":[{"categories":[{"measurements":[{"comment":"Upper CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"15.9","upperLimit":"NA","value":"19.6"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"9.5","value":"8.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \\[CR\\] or partial response \\[PR\\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), who received investigator's choice treatment, Trastuzumab/Capecitabine or Lapatinib/Capecitabine.","id":"OG001","title":"Treatment of Investigator's/Physician's Choice (TPC)"}],"paramType":"MEDIAN","populationDescription":"Duration of Response (DoR) was assessed in the Full Analysis Set of participants with confirmed CR/PR at data cut-off date of 30 Jun 2022.","reportingStatus":"POSTED","timeFrame":"Baseline up to 46 months postdose","title":"Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine","type":"SECONDARY","unitOfMeasure":"months"}